Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by Invesco Ltd

ENTA CUSIP 29251M106 Manager CIK 0000914208

Reported 106,168 shares, down 174,996 (62.2%) from the prior quarter.

Reported value -51.3%; share count -62.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2021
Shares 106,168 Quarter-end amount reported
Reported value $6,032,000 Fair value at quarter end
Consecutive quarters held 31 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 6032000
2021-12-31 21674000
2022-03-31 24343000
2022-06-30 23613000
2022-09-30 18474000
2022-12-31 4958987
2023-03-31 12203579
2023-06-30 1800233
2023-09-30 207382
2023-12-31 190383
2024-03-31 759492
2024-06-30 562432
2024-09-30 449914
2024-12-31 268031
2025-03-31 332730
2025-06-30 475403
2025-09-30 714585
2025-12-31 4002599
2026-03-31 2298685
2026-06-30 867948

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ENANTA PHARMACEUTICALS INC held by Invesco Ltd.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 59,530 -122,472 (-67.3%) < 0.01% $867,948 2026-08-14
Q1 2026 Reduced 182,002 -71,809 (-28.3%) < 0.01% $2,298,685 2026-05-12
Q4 2025 Added 253,811 +194,113 (325.2%) < 0.01% $4,002,599 2026-02-19
Q3 2025 Reduced 59,698 -3,186 (-5.1%) < 0.01% $714,585 2025-11-13
Q2 2025 Added 62,884 +2,607 (4.3%) < 0.01% $475,403 2025-08-13
Q1 2025 Added 60,277 +13,663 (29.3%) < 0.01% $332,730 2025-05-12
Q4 2024 Added 46,614 +3,186 (7.3%) < 0.01% $268,031 2025-02-13
Q3 2024 Added 43,428 +64 (0.1%) < 0.01% $449,914 2024-11-12
Q2 2024 Reduced 43,364 -135 (-0.3%) < 0.01% $562,432 2024-08-13
Q1 2024 Added 43,499 +23,267 (115.0%) < 0.01% $759,492 2024-05-14
Q4 2023 Added 20,232 +1,666 (9.0%) < 0.01% $190,383 2024-02-13
Q3 2023 Reduced 18,566 -65,557 (-77.9%) < 0.01% $207,382 2023-11-13
Q2 2023 Reduced 84,123 -217,647 (-72.1%) < 0.01% $1,800,233 2023-08-11
Q1 2023 Added 301,770 +195,171 (183.1%) < 0.01% $12,203,579 2023-05-12
Q4 2022 Reduced 106,599 -249,578 (-70.1%) < 0.01% $4,958,987 2023-02-13
Q3 2022 Reduced 356,177 -143,353 (-28.7%) < 0.01% $18,474,000 2022-11-14
Q2 2022 Added 499,530 +157,523 (46.1%) < 0.01% $23,613,000 2022-08-15
Q1 2022 Added 342,007 +52,163 (18.0%) < 0.01% $24,343,000 2022-05-16
Q4 2021 Added 289,844 +183,676 (173.0%) < 0.01% $21,674,000 2022-02-14
Q3 2021 Reduced 106,168 -174,996 (-62.2%) < 0.01% $6,032,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

159 managers reported ENANTA PHARMACEUTICALS INC for Q3 2021.

Managers reporting ENANTA PHARMACEUTICALS INC in Q3 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 3,595,053 -76,953 < 0.01% $204,237,000 30 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 1,995,000 0 0.53% $113,336,000 17 qtrs
ARMISTICE CAPITAL LLC Reduced 1,836,000 -164,000 1.77% $104,303,000 22 qtrs
VANGUARD GROUP INC Reduced 1,800,363 -56,656 < 0.01% $102,278,000 34 qtrs
STATE STREET CORPORATION Added 1,072,182 +18,107 < 0.01% $60,911,000 33 qtrs
FIRST MANHATTAN CO Added 969,736 +936,536 0.2% $55,090,000 21 qtrs
NORTHERN TRUST CORPORATION Added 959,048 +310,246 < 0.01% $54,483,000 34 qtrs
Krensavage Asset Management LLC Reduced 936,777 -2,873 16.69% $53,218,000 27 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 756,585 -41,143 0.06% $42,982,000 23 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 610,866 -33,922 0.01% $34,703,000 27 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 15, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
97,456
None
8,712

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.